Not available
Quote | Moleculin Biotech Inc. (NASDAQ:MBRX)
Last: | $3.49 |
---|---|
Change Percent: | 4.96% |
Open: | $3.45 |
Close: | $3.49 |
High: | $3.61 |
Low: | $3.37 |
Volume: | 10,734 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
News | Moleculin Biotech Inc. (NASDAQ:MBRX)
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...
Message Board Posts | Moleculin Biotech Inc. (NASDAQ:MBRX)
Subject | By | Source | When |
---|---|---|---|
We all have witnessed this stock with good | TheSprinx | investorshub | 04/20/2023 3:18:19 PM |
$MBRX THIS IS GOOD >>---> As of December | TheFinalCD | investorshub | 04/19/2023 11:50:12 AM |
Recent Highlights | TheFinalCD | investorshub | 04/19/2023 11:48:28 AM |
.75 walk down on air shares this morning | TheFinalCD | investorshub | 04/19/2023 9:15:37 AM |
https://www.prnewswire.com/news-releases/moleculin-announces-presentation-of-pos | Dennisb68 | investorshub | 04/18/2023 10:47:05 PM |
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...
Moleculin to Present at the Virtual Investor Pitch Conference PR Newswire Live video webcast on Tuesday, June 18 th at 3:00 PM ET HOUSTON , June 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company...